Imfinzi puts its flag on the Matterhorn
A hit on EFS will challenge regulators, and points to Merck's design blunder in Keynote-585.
Merck and Sanofi sound the alarm for ILT inhibition
Merck & Co gives up on Agenus, while Sanofi hands BND-22 back to Biond.
Amgen looks for Five Prime payback
A key pivotal study of bemarituzumab will read out shortly.
What future for Lag3 blockade?
Opdualag chalks up another failure, this time in the extension of an approved use.
